Neurological outcome after emergency radiotherapy in MSCC of patients with non-small cell lung cancer - a prospective trial

Radiation Oncology

Florian Sterzing²  Jürgen Debus²  Arash Moghaddam-Alvandi¹  Thomas Bruckner³  Stefan Rieken²  Lina C Petersen²  Rita C Heinhold²  Harald Rief² 

[1] Department of Orthopaedics, Trauma & Paraplegiologie, University Hospital of Heidelberg, Schlierbacher Landstraße 200a, 69118 Heidelberg, Germany;Department of Radiation Oncology, University Hospital of Heidelberg, Im Neuenheimer Feld 400, 69120 Heidelberg, Germany;Department of Medical Biometry, University Hospital of Heidelberg, Im Neuenheimer Feld 305, 69120 Heidelberg, Germany

关键词: Neurological outcome;    Spine;    MSCC;    Emergency radiotherapy;   

Others  :  829321
DOI  :  10.1186/1748-717X-8-297

 received in 2013-11-26, accepted in 2013-12-26,  发布年份 2013

【 摘 要 】

Background

The aim of this trial was to investigate neurological outcome after emergency RT in MSCC of NSCLC patients with acute neurological deficit.

Methods

This pilot trial was prospective, non-randomized, and monocentre, ten patients were treated from July 2012 until June 2013. After onset of neurological symptoms RT was started within 12 hours. The neurological outcome was assessed at baseline, and six weeks after RT using the ASIA Impairment Scale (AIS).

Results

The results showed an improved neurological outcome in one patient (10%), one patient (10%) had a decreased, and five patients (50%) a constant outcome after six weeks. Three patients (30%) died within the first six weeks following RT, additional 4 patients (40%) died within 4 month due to tumor progression.

Conclusion

In this group of NSCLC patients we were able to show that emergency RT in MSCC with acute neurological deficit had no considerable benefit in neurological outcome. Therefore, short-course regime or best supportive care due to poor survival should be considered for these patients with additional distant metastases. Patients with favorable prognosis may be candidates for long-course RT.

Trial Registration

Clinical trial identifier NCT 02000518.

【 授权许可】

   
2013 Rief et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 2.

【 参考文献 】

• [1]Rades D, Fehlauer F, Schulte R, et al.: Prognostic factors for local control and survival after radiotherapy of metastatic spinal cord compression. J Clin Oncol 2006, 24:3388-3393.
• [2]Bach F, Larsen BH, Rohde K, et al.: Metastatic spinal cord compression, occurrence, symptoms, clinical presentations and prognosis in 398 patients with spinal cord compression. Acta Neurochir 1990, 107:37-43.
• [3]Prasad D, Schiff D: Malignant spinal-cord compression. Lancet Oncol 2005, 6(1):15-24.
• [4]Yeung SCJ, Escalante CP: Oncologic emergencies. In Holland-Frei Cancer Medicine. Seventh edition. Edited by Kufe DW, Bast RC, Hait W, Kufe DW, Bast RC, Hait W. Hamilton, Ontario: BC Decker; 2006:2328.
• [5]Christian E, Adamietz IA, Willich N, et al.: Radiotherapy in oncological emergencies – final results of a patterns of care study in Germany, Austria and Switzerland. Acta Oncol 2008, 47:81-89.
• [6]El M, Tsobo M, Katoh S, et al.: Validation of the American spinal injury association (ASIA) motor score and the national acute spinal cord injury study (NASCIS) motor score. Spine 1996, 21(5):614-619.
• [7]Loblaw DA, Laperriere NJ: Emergency treatment of malignant extradural spinal cord compression: an evidence-based guidline. J Clin Oncol 1998, 16(4):1613-1624.
• [8]Rades D, Huttenlocher S, Evers NJ, et al.: Do elderly patients benefit from surgery in addition to radiotherapy for treatment of metastatic spinal cord compression? Strahlenther Onkol 2012, 188:424-430.
• [9]Rades D, Fehlauer F, Stalpers LJ, et al.: A prospective evaluation of two radiotherapy schedules with 10 versus 20 fractions for the treatment of metastatic spinal cord compression: final results of a multicenter study. Cancer 2004, 101(11):2687-2692.
• [10]Maranzano E, Bellavita R, Rossi R, et al.: Short-course versus split-course radiotherapy in metastatic spinal cord compression: results of a phase III, randomized, multicenter trial. J Clin Oncol 2005, 23(15):3358-3365.
• [11]Krassioukov A, Biering-Sørensen F, Donovan W, et al.: International standards to document remaining autonomic function after spinal cord injury. J Spinal Cord Med 2012, 35(4):201-210.
• [12]Hoskin PJ, Grover A, Bhana R: Metastatic spinal cord compression: radiotherapy outcome and dose fractionation. Radiother Oncol 2003, 68:175-180.
• [13]Prewett S, Venkitaraman R: Metastatic spinal cord compression: review of the evidence for a radiotherapy dose fractionation schedule. Clin Oncol 2010, 22:222-230.
• [14]Rades D, Veninga T, Bajrovic A, et al.: A validated scoring system to identify long-term survivors after radiotherapy for metastatic spinal cord compression. Strahlenther Onkol 2013, 189:462-466.
• [15]Rades D, Douglas S, Veninga T, et al.: A validated survival score for patients with metastatic spinal cord compression from non-small cell lung cancer. BMC Cancer 2012, 12:302. BioMed Central Full Text
• [16]Loblaw DA, Mitera G: The optimal dose fractionation schema for malignant extradural spinal cord compression. J Support Oncol 2011, 9(4):121-124.
• [17]Sorensen S, Helweg-Larsen S, Mouridsen H, Hansen HH: Effect of high-dose dexamethasone in carcinomatous metastatic spinal cord compression treated with radiotherapy: a randomized trial. Eur J Cancer 1994, 30:22-27.